Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 11th Preview)
-
Regulatory setbacks and pipeline readouts in immune and cancer indications
Sanofi moved to stop its Phase 3 MOBILIZE trial of riliprubart in chronic inflammatory demyelinating polyneuropathy after an interim analysis found the antibody was unlikely to provide sufficient efficacy, despite no safety concerns reported. The decision also raises new questions for the complement-inhibitor approach in CIDP after earlier setbacks in the class and amid competitive pressure. In parallel, Gilead pulled the plug on Trodelvy (sacituzumab govitecan) plus Keytruda in the Phase 3 Evoke-03 (Keynote-D46) first-line PD-L1-high non-small cell lung cancer trial. The study missed progression-free survival at final analysis, and overall survival was deemed unlikely to achieve statistical significance. Taken together, the two decisions underscore how quickly late-stage evidence can shift treatment landscapes in both autoimmune neurology and oncology, and may redirect attention to next-generation assets and competitors as 2026 regulatory timelines tighten.
-
Large-cap acquisitions to expand oncology portfolios
GSK agreed to acquire Nuvalent for $10.6 billion, adding near-commercial and clinical-stage targeted programs for NSCLC. The deal brings zidesamtinib (NVL-520) and eladalkib (NVL-655), both designed to address resistance in ROS1- and ALK-driven disease and positioned for potential launches later this year if FDA reviews finish on schedule. Nuvalent’s pipeline also includes NVL-330, a HER2 inhibitor in early development. The acquisition is structured to strengthen GSK’s oncology growth engine with assets carrying Breakthrough Therapy and Orphan Drug designations, including planned FDA decision dates later in 2026. For investors and competitors, the transaction signals continued appetite for precision oncology programs where target selectivity and brain penetration are central to differentiation.
-
Gene therapy in the clinic: early safety signals for XLRS
A Chinese research team reported safety and feasibility of a subretinal AAV8 gene therapy delivering a codon-optimized RS1 transgene for pediatric X-linked retinoschisis (XLRS), with results appearing in the New England Journal of Medicine. The study enrolled a dozen patients aged 5 to 18, using an AAV8 construct designed for more specific photoreceptor expression. The approach is positioned as a potential shift from supportive care to early molecular intervention if further efficacy signals emerge. The paper also notes that Chengdu Genevector helped design and manufacture the clinical-grade vectors. Atsena Therapeutics is concurrently evaluating ATSN-201, another subretinal AAV vector program for XLRS, highlighting growing clinical interest in RS1 replacement delivered directly to retinal photoreceptors.
-
Non-viral gene delivery funding and trial push
SonoThera raised $125 million to advance its ultrasound-based, microbubble-mediated non-viral gene delivery platform into clinical development. The financing is intended to propel lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease. The company’s strategy focuses on using ultrasound to activate microbubbles after administration of nucleic acids, aiming to improve delivery safety and broaden applicability beyond rare diseases, while addressing limitations associated with viral vectors and conventional lipid nanoparticles. For the gene therapy sector, the round reflects sustained funding interest in delivery innovations designed to overcome durability, dosing, and manufacturing bottlenecks.
-
Diagnostics and regulatory expansion in molecular testing
OraSure Technologies received FDA 510(k) clearance for an at-home urine sample collection kit for sexually transmitted infection (STI) testing on Roche systems. The Colli-Pee kit supports self-collection of first-void urine followed by molecular detection for multiple pathogens, with room-temperature stabilization using OraSure’s NucleoPrecision chemistry. The clearance is intended to expand access to screening programs by enabling prescriptions for home collection and direct shipping of specimens to laboratories. Guardant Health also secured an FDA approval for Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s HER2-mutant lung cancer drug Hernexeos, marking another broadening of liquid-biopsy-guided oncology decisions.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.